PTC Therapeutics
Email page Email Page  Print Page Print Page  Glossary Glossary  Site Map Site Map
 Ataluren for Genetic
 Disorders
 Phase 2b DMD/BMD
 Trial Sites
 PTC299 Oncology

Ataluren (PTC124™) for Genetic Disorders

PTC is currently developing ataluren, a novel, orally administered, small-molecule, investigational new drug for the treatment of genetic disorders in which a nonsense mutation is the cause of disease.

For more information on our clinical results, or ataluren, please visit the ataluren page of our website.


Ataluren Genetic Disorders

PTC299 Oncology

 

 

 

 

 

 

 

 

 

 

Contact Us
To sign up to receive PTC updates or send a question please click below

Learn More ยป